Sanjivani Paranteral Limited , a prominent player in the pharmaceutical industry, has announced a significant addition to its leadership team. The company's Board of Directors has appointed Mr. Basant Shrivastava as an Additional Director under the Independent Category, effective September 11, 2025. This appointment, subject to shareholder approval at the upcoming Annual General Meeting, marks a strategic move to enhance the company's governance and industry expertise.

Appointment Details

Mr. Shrivastava, holding the Director Identification Number (DIN) 02645245, has been appointed for a five-year term as a Non-Executive Independent Director. The decision comes on the recommendation of the Nomination and Remuneration Committee, underlining the company's commitment to strengthening its board with experienced professionals.

Professional Background

Basant Shrivastava brings an impressive four decades of pharmaceutical industry experience to Sanjivani Paranteral. His educational background includes:

• M.Sc. in Chemistry
• MBA from the Jamnalal Bajaj Institute of Management Studies

Throughout his career, Shrivastava has held several leadership positions that showcase his expertise in the pharmaceutical sector:

Expertise and Achievements

Mr. Shrivastava is renowned for his sales and marketing acumen in the pharmaceutical industry. His career highlights include:

• Driving growth and launching new ventures
• Leading high-performing teams
• Spearheading operations in contrast media products
• Successfully transitioning businesses to adapt to evolving market dynamics
• Achieving numerous sales awards and consistently ranking among top performers

Board Meeting Outcome

The appointment was approved during a board meeting held on September 11, 2025. The meeting, which commenced at 06:30 P.M. and concluded at 07:00 P.M., also addressed other company matters.

Corporate Governance

It's worth noting that Mr. Shrivastava is not related to any existing directors of Sanjivani Paranteral Limited, ensuring independence in his role. This appointment aligns with the company's commitment to maintaining strong corporate governance practices.

The addition of Basant Shrivastava to Sanjivani Paranteral's board is expected to bring valuable insights and strategic direction, leveraging his extensive experience in the pharmaceutical industry. Shareholders will have the opportunity to ratify this appointment at the forthcoming Annual General Meeting, as the company continues to strengthen its leadership for future growth and success.

Sanjivani Parenteral Limited has announced the commencement of commercial production at its new intravenous (IV) fluid infusion plant in Pune, Maharashtra. This strategic move marks a significant expansion in the company's manufacturing capabilities and opens up a new revenue stream in the healthcare sector.

State-of-the-Art Facility

The newly established plant, operated by SPL Infusion Pvt. Ltd., a subsidiary of Sanjivani Parenteral, began commercial production on September 6, 2025. The facility has been designed with a dual focus on efficiency and sustainability, incorporating advanced technology to enhance product quality and improve consistency.

Strategic Location

Located in Pune, the plant is strategically positioned to serve both domestic and export markets. The city's proximity to leading pharmaceutical clusters and hospitals, coupled with robust infrastructure and strong supply-chain connectivity, is expected to facilitate efficient distribution of IV fluids.

Sustainability Initiatives

In line with modern manufacturing practices, the facility has integrated eco-friendly features. Notable among these is the installation of solar panels, which will provide a green electricity supply. This initiative is anticipated to lower electricity consumption and reduce long-term operating costs, aligning with the company's commitment to sustainable operations.

Regulatory Compliance

Sanjivani Parenteral confirmed that the plant has received the necessary manufacturing license from the concerned authorities, ensuring compliance with regulatory standards before commencing operations.

Market Impact

The launch of this new IV fluid infusion plant represents a pivotal milestone in Sanjivani Parenteral's growth strategy. By expanding its manufacturing scale and establishing a new revenue vertical, the company aims to strengthen its position in the healthcare and pharmaceutical manufacturing sector.

Ravikumar Bogham, Company Secretary Cum Compliance Officer of Sanjivani Parenteral Limited, stated in the company's official communication to the BSE, "This development marks a pivotal milestone in the Company's growth journey, as it expands manufacturing scale, establishes a new revenue vertical, and further strengthens its position in the healthcare and pharmaceutical manufacturing sector."

As the healthcare sector continues to evolve, Sanjivani Parenteral's new facility is poised to meet the growing demand for IV fluids, both in India and international markets. The company's investment in advanced technology and sustainable practices demonstrates its commitment to quality and environmental responsibility in pharmaceutical manufacturing.